Ipsen Biopharmaceuticals
Ipsen Biopharmaceuticals, Inc.
One Main Street,
Cambridge, MA 02142
Phone: (617) 679-5600Website: https://www.ipsen.com/us/Careers: www.ipsen.com/us/careers
Latest news
- FDA Grants Accelerated Approval to Iqirvo (elafibranor) for the Treatment of Primary Biliary Cholangitis
10 June 2024 - Ipsen’s Onivyde Regimen, a Potential New Standard-of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA
13 February 2024 - Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare Cholestatic Liver Disease, PBC
7 December 2023 - FDA Approves Sohonos (palovarotene) for the Treatment of Fibrodysplasia Ossificans Progressiva
16 August 2023 - Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, a Rare Cholestatic Liver Disease
30 June 2023 - FDA Approves Bylvay for Patients Living with Cholestatic Pruritus Due to Alagille Syndrome
13 June 2023 - Ipsen Receives Complete Response Letter for Palovarotene, an Investigational Treatment for Fibrodysplasia Ossificans Progressiva
23 December 2022 - Ipsen Announces U.S. FDA Priority Review for Palovarotene New Drug Application in Patients With Fibrodysplasia Ossificans Progressiva Following Resubmission
29 June 2022 - Ipsen Announces Withdrawal of Palovarotene NDA, Confirming Intention to Resubmit Following Additional Data Analyses
13 August 2021 - FDA Approves Bylvay (odevixibat) for the Treatment of Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)
20 July 2021
Drugs Associated with Ipsen Biopharmaceuticals, Inc.
Ipsen Biopharmaceuticals, Inc. manufactures, markets and/or distributes more than 8 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Bylvay
Generic name: odevixibat Drug class: miscellaneous GI agents |
||
|
Dysport
Generic name: abobotulinumtoxinA Drug class: skeletal muscle relaxants |
9 reviews | 4.7 / 10 |
|
Increlex
Generic name: mecasermin Drug class: insulin-like growth factors |
||
|
Iqirvo
Generic name: elafibranor Drug class: miscellaneous metabolic agents |
||
|
Onivyde
Generic name: irinotecan liposomal Drug class: miscellaneous antineoplastics |
||
|
Sohonos
Generic name: palovarotene Drug class: miscellaneous uncategorized agents |
||
|
Somatuline Depot
Generic name: lanreotide Drug class: somatostatin and somatostatin analogs |
1 review | 8.0 / 10 |
|
Tazverik
Generic name: tazemetostat Drug class: miscellaneous antineoplastics |
2 reviews | 9.5 / 10 |
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||